Page last updated: 2024-08-24

ruthenium chloride (rucl3) and Adenocarcinoma

ruthenium chloride (rucl3) has been researched along with Adenocarcinoma in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	1 (100.00)	2.80

Authors

Authors	Studies
Li, K; Li, W; Liang, L; Long, D; Zeng, J; Zhao, Y	1

Other Studies

1 other study(ies) available for ruthenium chloride (rucl3) and Adenocarcinoma

Article	Year
A coordinated ruthenium-rifampicin complex reprogramming the colon carcinoma micro-environment mediated by modulation of p53/AkT/mTOR/VEGF pathway. Toxicology and applied pharmacology, 2021, 09-01, Volume: 426 Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Apoptosis; Cell Cycle; Colon; Colonic Neoplasms; Drug Combinations; Female; HCT116 Cells; HT29 Cells; Humans; Male; Mice, Inbred BALB C; Proto-Oncogene Proteins c-akt; Rats, Wistar; Rifampin; Ruthenium Compounds; Signal Transduction; TOR Serine-Threonine Kinases; Tumor Microenvironment; Tumor Suppressor Protein p53; Vascular Endothelial Growth Factor A	2021

Article

Year

A coordinated ruthenium-rifampicin complex reprogramming the colon carcinoma micro-environment mediated by modulation of p53/AkT/mTOR/VEGF pathway.

Toxicology and applied pharmacology, 2021, 09-01, Volume: 426

Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Apoptosis; Cell Cycle; Colon; Colonic Neoplasms; Drug Combinations; Female; HCT116 Cells; HT29 Cells; Humans; Male; Mice, Inbred BALB C; Proto-Oncogene Proteins c-akt; Rats, Wistar; Rifampin; Ruthenium Compounds; Signal Transduction; TOR Serine-Threonine Kinases; Tumor Microenvironment; Tumor Suppressor Protein p53; Vascular Endothelial Growth Factor A

2021